Abstract
Spindle pole body component 25 (SPC25) is a component of NDC80 complex that controls spindle assembly checkpoint in the microtubule-binding domain of kinetochores. We recently showed that SPC25 is required for prostate cancer (PrC) cell proliferation and cell cycle progression, and here we investigated whether SPC25 may be a Cancer stem cell (CSC) marker in PrC. We found that the levels of SPC25 were higher in PrC samples than paired normal prostate tissue. The overall survival of PrC patients with high SPC25 was poorer than those with low SPC25. PrC cell lines were transduced with two vectors carrying a luciferase reporter and a mCherry fluorescent reporter under a cytomegalovirus promoter and a nuclear green fluorescent protein reporter under the control of a SPC25 promoter, respectively, to allow differentiating SPC25+ from SPC25- PrC cells by flow cytometry. Compared to SPC25- cells, SPC25+ cells formed significantly more tumor spheres in culture, appeared to be more resistant towards docetaxel-induced cell apoptosis, and generated larger tumors with higher frequency after serial adoptive transplantation. Thus, our data suggest that SPC25 may be highly expressed in the CSC-like cells in PrC and could be a promising target for effective treatment of PrC.
Highlights
Prostate cancer (PrC) is the most diagnosed malignant cancer in aged Chinese men [1]
We recently showed that Spindle pole body component 25 (SPC25) is required for prostate cancer (PrC) cell proliferation and cell cycle progression, and here we investigated whether SPC25 may be a Cancer stem cell (CSC) marker in PrC
The all 40 patients included in this study were followed up for 5 years to analyze the association between the SPC25 protein levels in the PrC specimens and the overall survival of the patients
Summary
Prostate cancer (PrC) is the most diagnosed malignant cancer in aged Chinese men [1]. Typical PrCs are generated by small knots of malignant cells that grow in a slow speed within the prostate gland, and are well responsive to stimulation of androgen [2]. In rare situations, PrC cells may increase proliferation, migrate out of the prostate gland to distant tissue, and their growth can even become less dependent or independent on androgen[3], as castration-resistant prostate cancer (CRPC) [4]. The most effective chemotherapeutic drug for metastatic PrC is docetaxel [7]. Both surface and nonsurface biomarkers have been used to identify and purify CSCs but the specificity of a certain CSC marker is limited, in which none of markers is able to purify true CSCs, but to enrich them [8]. Since isolated “CSCs” by these markers only enriched CSC population, these purified “CSCs”
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
